article thumbnail

The US Just Approved The First Over-The-Counter Daily Birth Control Pill

AuroBlog - Aurous Healthcare Clinical Trials blog

The pill, called Opill – the brand name for the tablet formulation of norgestrel – is an oral contraceptive containing only progestin hormone, which helps prevent pregnancy […]

Hormones 182
article thumbnail

Pharmanovia signs licence deal for Aeterna Zentaris’ Ghryvelin

Pharmaceutical Technology

Ghryvelin is used for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare and serious condition, as well as for Childhood Onset Growth Hormone Deficiency (CGHD), if approved. Macimorelin is marketed under the brand name Ghryvelin in the EEA and the UK.

Hormones 263
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Thyroid Awareness Month 2024: Increasing Awareness and Exploring New Treatments for Thyroid Diseases

XTalks

The thyroid plays a critical role in the body by producing hormones that regulate metabolism, heart rate and body temperature among others. Types of Thyroid Conditions There are several different thyroid conditions, with each affecting thyroid hormone production or the gland’s structure, leading to a range of health issues.

Hormones 105
article thumbnail

Orion’s darolutamide receives Japan’s MHLW approval for prostate cancer

Pharmaceutical Technology

Previously, the inhibitor, under the brand name Nubeqa, received approval to treat non-metastatic castration-resistant prostate cancer (nmCRPC) patients in the country. The trial assessed the safety and efficacy of oral darolutamide plus ADT and chemotherapy docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC) patients.

Hormones 130
article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

This growth is primarily due to market release of several gonadotropin-releasing hormone (GnRH) receptor antagonists, including Myovant’s Myfembree (relugolix, estradiol, and norethindrone acetate) in the US, and its upcoming launch in the 5EU, where it will be sold under the brand name Ryeqo.

Marketing 147
article thumbnail

FDA clears Myovant’s relugolix for uterine fibroids, setting up AbbVie clash

pharmaphorum

The drug will be sold as Myfembree (relugolix) for the uterine fibroids indication, and is already available to treat prostate cancer under the Orgovyx brand name. Combining it with the hormonal drugs reduces side effects – such as bone loss – that can result from reducing oestrogen levels.

article thumbnail

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval

Pharmaceutical Technology

Douglas provides products in various therapeutic areas which include psoriasis, eczema, dermatitis, chicken pox, constipation, laxative, neonatal, hormone regulation, dermatology, cardiovascular and measles, among others. The company also offers contract manufacturing and laboratory services.